The durvalumab (anti-PDL1) gene signature generated in urothelial cancer was shown to have a strong positive correlation with IL2RB expression in both the CRC microarray and RNA-seq pipelines (Supplementary Figure S5A and B, R = 0.87, P < 0.0001 and R = 0.82, P < 0.0001) (36). This evidence concerns the gene IL2RB and colorectal carcinoma.